Invesco Ltd. Grows Stock Holdings in Charles River Laboratories International, Inc. (NYSE:CRL)

Invesco Ltd. lifted its stake in Charles River Laboratories International, Inc. (NYSE:CRL) by 17.1% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,034,180 shares of the medical research company’s stock after purchasing an additional 151,159 shares during the quarter. Invesco Ltd.’s holdings in Charles River Laboratories International were worth $190,910,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors also recently made changes to their positions in the stock. Versant Capital Management Inc boosted its holdings in Charles River Laboratories International by 1,071.4% in the fourth quarter. Versant Capital Management Inc now owns 164 shares of the medical research company’s stock worth $30,000 after acquiring an additional 150 shares in the last quarter. Pinnacle Bancorp Inc. increased its holdings in shares of Charles River Laboratories International by 52.0% during the fourth quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company’s stock valued at $35,000 after acquiring an additional 65 shares in the last quarter. Pilgrim Partners Asia Pte Ltd purchased a new position in shares of Charles River Laboratories International in the 4th quarter worth about $48,000. Tortoise Investment Management LLC boosted its stake in Charles River Laboratories International by 77.7% in the 4th quarter. Tortoise Investment Management LLC now owns 263 shares of the medical research company’s stock worth $49,000 after purchasing an additional 115 shares in the last quarter. Finally, Wilmington Savings Fund Society FSB purchased a new stake in Charles River Laboratories International during the 3rd quarter valued at about $59,000. Hedge funds and other institutional investors own 98.91% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on the stock. Mizuho decreased their target price on shares of Charles River Laboratories International from $175.00 to $155.00 and set a “neutral” rating for the company in a report on Wednesday. Citigroup upgraded shares of Charles River Laboratories International from a “sell” rating to a “neutral” rating and boosted their price objective for the stock from $155.00 to $175.00 in a report on Tuesday, March 4th. The Goldman Sachs Group downgraded Charles River Laboratories International from a “buy” rating to a “neutral” rating and cut their target price for the company from $190.00 to $170.00 in a research note on Friday, March 21st. UBS Group restated a “neutral” rating and issued a $185.00 price target (down previously from $250.00) on shares of Charles River Laboratories International in a research note on Friday, January 17th. Finally, Barclays lowered their price target on Charles River Laboratories International from $160.00 to $145.00 and set an “equal weight” rating on the stock in a report on Thursday. One research analyst has rated the stock with a sell rating and sixteen have assigned a hold rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $182.00.

Insider Transactions at Charles River Laboratories International

In other Charles River Laboratories International news, EVP Joseph W. Laplume sold 4,400 shares of the company’s stock in a transaction dated Thursday, February 20th. The stock was sold at an average price of $162.50, for a total value of $715,000.00. Following the completion of the sale, the executive vice president now owns 20,013 shares in the company, valued at $3,252,112.50. This represents a 18.02 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, COO Birgit Girshick acquired 1,514 shares of the stock in a transaction dated Thursday, February 20th. The shares were bought at an average cost of $164.63 per share, for a total transaction of $249,249.82. Following the completion of the transaction, the chief operating officer now owns 55,058 shares in the company, valued at approximately $9,064,198.54. This represents a 2.83 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Corporate insiders own 1.30% of the company’s stock.

Charles River Laboratories International Stock Down 0.4 %

CRL stock opened at $99.56 on Friday. The company has a market cap of $4.89 billion, a price-to-earnings ratio of 663.71, a P/E/G ratio of 4.54 and a beta of 1.45. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.14 and a current ratio of 1.41. The business’s 50-day moving average is $156.71 and its two-hundred day moving average is $177.01. Charles River Laboratories International, Inc. has a fifty-two week low of $91.86 and a fifty-two week high of $254.15.

Charles River Laboratories International (NYSE:CRL) last issued its quarterly earnings data on Wednesday, February 19th. The medical research company reported $2.66 earnings per share for the quarter, topping the consensus estimate of $2.50 by $0.16. The firm had revenue of $1 billion for the quarter, compared to analysts’ expectations of $983.63 million. Charles River Laboratories International had a net margin of 0.52% and a return on equity of 14.69%. The business’s quarterly revenue was down 1.1% on a year-over-year basis. During the same quarter in the prior year, the business earned $2.46 EPS. As a group, analysts forecast that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current year.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).